SAN DIEGO, March 9, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of Ibudilast for the treatment of drug addiction or drug dependence or withdrawal syndrome. Ibudilast, aka MN-166 or AV411, is the company's lead drug candidate for certain neurological conditions, including neuropathic pain, drug addiction and progressive multiple sclerosis.
The patent, once issued, covers the use of ibudilast for therapeutic administration alone or in combination with other drugs for the treatment of opioid addiction, dependence, or withdrawal syndrome. Ibudilast is a non-opioid inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterases-4 and -10 (PDEs-4, -10) and has been shown to reduce glial cell activation. Such a cellular action has been experimentally linked to certain neurochemical and behavioral changes associated with addiction to drugs like opioids and methamphetamine. The patent application is based upon research by Linda Watkins, Ph.D., and colleagues at University of Colorado, Boulder, and Kirk Johnson, Ph.D., Chief Scientific Officer, at MediciNova. As mentioned above, the allowed claims include a method of treating an opioid withdrawal syndrome, which is sometimes observed in patients who stop or reduce their use of opioids like morphine and oxycodone (i.e., Vicodin®), and the reduction of associated glial cell activation. The allowed claims also cover the use of ibudilast in combination with buprenorphine, itself an opioid, which is approved (i.e., Suboxone®) for treating opioid dependence.
Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, noted that "We are very pleased to receive notice of this patent allowance for ibudilast in drug addiction, especially on the heels of our recent announcement of encouraging preliminary clinical trial results in morphine withdrawal and analgesia." Dr. Iwaki added that "Positive progress in our MN-166 program along with our ongoing phase 2 asthma exacerbation trial with another of our lead drug candidates, MN-221, speaks to our pipeline quality."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV